[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604846":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":140,"collaborators":10,"id":142,"slug":143,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":144,"sex":149,"minAge":150,"maxAge":10,"enrollmentInfo":151,"targetDuration":154,"studyType":155,"phases":10,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Tempus AI","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 001: Newly Diagnosed Acute Myeloid Leukemia (AML)",null,"Newly diagnosed patients with a primary or secondary diagnosis of Acute Myeloid Leukemia (AML)",[13],"Other: None - Observational Study",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 002: Folicular Lymphoma","Cohort 002 contains four subgroups of Follicular Lymphoma (FL): A: Newly Diagnosed FL on Active Observation; B: Newly Diagnosed High Risk FL; C: Relapsed \u002F Refractory High Risk POD24 FL; D: Transformed FL",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","None - Observational Study","There are no interventions in this observational study.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Michael Thompson, MD, PhD, FASCO","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Aquarius Clinical Study Manager","CONTACT","800-739-4137","aquarius@tempus.com",[35,56,74,91,107,124],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The Center for Cancer and Blood Disorders","RECRUITING","Bethesda","Maryland","20817","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-77.10026,38.98067,{"lat":47,"lon":46},[50,54],{"name":51,"role":31,"phone":52,"phoneExt":10,"email":53},"Kosunique Jenkins","301-571-0019","ven.mdbet.KJenkins@aoncology.com",{"name":55,"role":27,"phone":10,"phoneExt":10,"email":10},"Shreya Desai",{"facility":57,"status":37,"city":58,"state":59,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Cancer Care Specialists of Reno","Reno","Nevada","89511",{"type":44,"coordinates":62},[63,64],-119.8138,39.52963,{"lat":64,"lon":63},[67,72],{"name":68,"role":31,"phone":69,"phoneExt":70,"email":71},"Layla Quinonez","775-329-0222","230","ltapia@ccsreno.com",{"name":73,"role":27,"phone":10,"phoneExt":10,"email":10},"Juan Adolfo Cattoni III",{"facility":75,"status":37,"city":76,"state":77,"zip":78,"country":41,"countryCode":42,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"University of Cincinnati","Cincinnati","Ohio","45219",{"type":44,"coordinates":80},[81,82],-84.51439,39.12711,{"lat":82,"lon":81},[85,89],{"name":86,"role":31,"phone":87,"phoneExt":10,"email":88},"Bethany Fuhrman","513-584-8162","fuhrmaba@ucmail.uc.edu",{"name":90,"role":27,"phone":10,"phoneExt":10,"email":10},"Emily Curran",{"facility":92,"status":37,"city":93,"state":77,"zip":94,"country":41,"countryCode":42,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Taylor Cancer Research Center","Maumee","43537",{"type":44,"coordinates":96},[97,98],-83.65382,41.56283,{"lat":98,"lon":97},[101,105],{"name":102,"role":31,"phone":103,"phoneExt":10,"email":104},"Jennifer Martinez","419-479-5605","JMartinez@tcrcpt.org",{"name":106,"role":27,"phone":10,"phoneExt":10,"email":10},"John Nemunaitis",{"facility":108,"status":37,"city":109,"state":110,"zip":111,"country":41,"countryCode":42,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Cancer Care Associates of York","York","Pennsylvania","17403",{"type":44,"coordinates":113},[114,115],-76.72774,39.9626,{"lat":115,"lon":114},[118,122],{"name":119,"role":31,"phone":120,"phoneExt":10,"email":121},"Clarissa Vega","717-741-9229","cvega@cancercareyork.com",{"name":123,"role":27,"phone":10,"phoneExt":10,"email":10},"Jackson Gao",{"facility":125,"status":37,"city":126,"state":127,"zip":128,"country":41,"countryCode":42,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Avera Cancer Institue","Sioux Falls","South Dakota","57105",{"type":44,"coordinates":130},[131,132],-96.72796,43.54369,{"lat":132,"lon":131},[135,138],{"name":136,"role":31,"phone":10,"phoneExt":10,"email":137},"Coordinator Contacts","ResearchAssistants@avera.org",{"name":139,"role":27,"phone":10,"phoneExt":10,"email":10},"Waqas Jehangir",{"type":141,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604846","a-longitudinal-multi-center-molecular-biomarker-discovery-registry-for-patients-with-hematologic-malignancies-100604846",false,"NCT07154823","A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies","Aquarius","All Cohorts Inclusion Criteria:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n\nCohort 001 Inclusion:\n\n1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification\n2. Secondary AML is allowed\n\nCohort 002 Inclusion:\n\n1. Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)\n2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)\n3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation\n4. 002B (Newly Diagnosed, High Risk): Intended for first line treatment\n5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)\n6. 002C (Relapsed \u002F Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment\n7. 002D (Transformed FL): Pathologically confirmed transformation\n\nAll Cohorts Exclusion Criteria:\n\n1\\. Not willing or able to adhere with the study procedures\n\nCohort 001:\n\n1\\. Have received any prior therapy intended for standard of care (SoC) treatment of AML\n\nCohort 002:\n\n1. 002A: Received prior treatment for follicular lymphoma\n2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN\n3. 002A: Resected patients with NED\n4. 002B: Intended for active observation\n5. 002B: Received prior treatment for follicular lymphoma","ALL","0 Years",{"count":152,"type":153},550,"ESTIMATED","5 Years","OBSERVATIONAL","The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and\u002For bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.",[158,159],"Acute Myeloid Leukaemia (AML)","Follicular Lymphoma ( FL)",[161,162,163,164,165,166],"Hematologic Malignancy","Acute Myeloid Leukemia","AML","Next Generation Sequencing","NGS","Follicular Lymphoma","2026-06-11",{"date":169,"type":170},"2026-06-15","ACTUAL",{"date":172,"type":170},"2026-01-27",{"date":174,"type":153},"2035-11",{"name":5,"class":6},6]